INSIGHT 2 : a Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance
Bron
Future oncology - ISSN 1479-6694- () p.
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2) : a multicentre, open-label, phase 2 trial
Bron
The lancet oncology - ISSN 1470-2045-25:8 (2024) p. 989-1002
A randomised phase II study of extended pleurectomy/ decortication preceded or followed by chemotherapy in patients with early-stage pleural mesothelioma : EORTC 1205
Bron
The European respiratory journal - ISSN 0903-1936-63:6 (2024) p. 1-12
Tepotinib treatment in patients with MET exon 14-skipping non-small cell lung cancer long-term follow-up of the VISION phase 2 nonrandomized clinical trial
Bron
JAMA oncology - ISSN 2374-2437-9:9 (2023) p. 1260-1266
Excess of blood eosinophils prior to therapy correlates with worse prognosis in mesothelioma
Bron
Frontiers in immunology - ISSN 1664-3224-14 (2023) p. 1-11